- May 16, 2017
Australian Biotech company launches clinical trials for revolutionary peanut allergy treatment
16 May 2017, Melbourne, Victoria – Australian biotechnology company Aravax has commenced clinical trials of a potentially life-changing product developed to treat sufferers of peanut allergy.
Aravax’s technology uses carefully selected fragments of peanut proteins to switch off allergic reactions. The product is designed to be safer, more rapid, and more convenient than other approaches currently under development. Aravax anticipates that simple, monthly injections will b